Patents by Inventor Yuti Chernajovsky
Yuti Chernajovsky has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20200062814Abstract: The present invention provides a fusion protein comprising a latency associated peptide (LAP), a pharmaceutically active agent and an amino acid sequence comprising a dimerisation domain, wherein the LAP and the pharmaceutically active agent are connected by an amino acid sequence comprising a proleolytic cleavage site. Also provided are nucleic acids enclosing such fusion proteins, process for their preparation, pharmaceutical compositions, kits and uses thereof in medicine.Type: ApplicationFiled: September 3, 2019Publication date: February 27, 2020Inventors: Yuti Chernajovsky, Lisa Mullen, Gillian Adams, David James Gould, Hawzheen Muhammad
-
Patent number: 10435451Abstract: The present invention provides a fusion protein comprising a latency associated peptide (LAP), a pharmaceutically active agent and an amino acid sequence comprising a dimerization domain, wherein the LAP and the pharmaceutically active agent are connected by an amino acid sequence comprising a proteolytic cleavage site. Also provided are nucleic acids enclosing such fusion proteins, process for their preparation, pharmaceutical compositions, kits and uses thereof in medicine.Type: GrantFiled: June 26, 2015Date of Patent: October 8, 2019Assignee: Stealthyx Therapeutics LimitedInventors: Yuti Chernajovsky, Lisa Mullen, Gillian Adams, David James Gould, Hawzheen Muhammad
-
Publication number: 20180221505Abstract: The present invention provides a composition comprising an antibody or fragment thereof against oxidised Collagen II (CII) in which the antibody or fragment thereof is conjugated to a pharmaceutically active moiety. The invention also provides a composition comprising an antibody or fragment thereof against oxidised Collagen II (Gil) and a detectable label. The invention further provides the use of such compositions in medicine, in particular for the treatment of an arthropathy, and in methods of diagnosis.Type: ApplicationFiled: December 18, 2017Publication date: August 9, 2018Inventors: Ahuva Nissim, Yuti Chernajovsky, Bjarne Faurholm, David Perrett, Paul Winyard, Christopher Hughes, Stephen Mather, Francesco Dell'Accio
-
Patent number: 9844602Abstract: The present invention provides a composition comprising an antibody or fragment thereof against oxidized Collagen II (CII) in which the antibody or fragment thereof is conjugated to a pharmaceutically active moiety. The invention also provides a composition comprising an antibody or fragment thereof against oxidized Collagen II (Gil) and a detectable label. The invention further provides the use of such compositions in medicine, in particular for the treatment of an arthropathy, and in methods of diagnosis.Type: GrantFiled: May 2, 2008Date of Patent: December 19, 2017Assignee: Queen Mary & Westfield CollegeInventors: Ahuva Nissim, Yuti Chernajovsky, Bjarne Faurholm, David Perrett, Paul Winyard, Christopher Hughes, Stephen Mather, Francesco Dell'Accio
-
Publication number: 20170129931Abstract: The present invention provides a fusion protein comprising a latency associated peptide (LAP), a pharmaceutically active agent and an amino acid sequence comprising a dimerisation domain, wherein the LAP and the pharmaceutically active agent are connected by an amino acid sequence comprising a proteolytic cleavage site. Also provided are nucleic acids enclosing such fusion proteins, process for their preparation, pharmaceutical compositions, kits and uses thereof in medicine.Type: ApplicationFiled: June 26, 2015Publication date: May 11, 2017Inventors: Yuti Chernajovsky, Lisa Mullen, Gillian Adams, David James Gould, Hawzheen Muhammad
-
Publication number: 20160228570Abstract: The present invention provides a composition comprising an antibody or fragment thereof against oxidised Collagen II (CII) in which the antibody or fragment thereof is conjugated to a pharmaceutically active moiety. The invention also provides a composition comprising an antibody or fragment thereof against oxidised Collagen II (CII) and a detectable label. The invention further provides the use of such compositions in medicine, in particular for the treatment of an arthropathy, and in methods of diagnosis.Type: ApplicationFiled: January 4, 2016Publication date: August 11, 2016Inventors: Ahuva Nissim, Yuti Chernajovsky, Bjarne Faurholm, David Perrett, Paul Winyard, Christopher Hughes, Stephen Mather, Francesco Dell'Accio
-
Patent number: 8357515Abstract: The present provides a fusion protein comprising a latency associated peptide (LAP) and a pharmaceutically active agent in which the LAP and the pharmaceutically active agent are connected by an amino acid sequence comprising an aggrecanase proteolytic cleavage site.Type: GrantFiled: December 17, 2008Date of Patent: January 22, 2013Assignee: Queen Mary & Westfield CollegeInventors: Yuti Chernajovsky, Gillian Adams
-
Publication number: 20110129415Abstract: The present invention provides a composition comprising an antibody or fragment thereof against oxidised Collagen II (CII) in which the antibody or fragment thereof is conjugated to a pharmaceutically active moiety. The invention also provides a composition comprising an antibody or fragment thereof against oxidised Collagen II (Gil) and a detectable label. The invention further provides the use of such compositions in medicine, in particular for the treatment of an arthropathy, and in methods of diagnosis.Type: ApplicationFiled: May 2, 2008Publication date: June 2, 2011Inventors: Ahuva Nissim, Yuti Chernajovsky, Bjarne Faurholm, David Perrett, Paul Winyard, Christopher Hughes, Stephen Mather, Francesco Dell'Accio
-
Publication number: 20110098226Abstract: The present invention relates to a receptor molecule which binds to TNF comprising all or a functional portion of the extracellular domain (ECD) of two or more TNF-Rs linked via one or more polypeptide linkers. The receptor can further comprise a signal peptide of a secreted protein, such as the signal peptide of the extracellular domain of the TNF-R or the signal peptide of a cytokine. The invention also relates to isolated DNA encoding a receptor molecule which binds to TNF, comprising two or more sequences encoding all or a functional portion of the ECD of TNF-Rs linked via one or more sequences encoding a polypeptide linker. The invention further relates to a method of making a construct which expresses all or a functional portion of the ECD of two or more TNF-Rs linked via one or more polypeptide linkers and cells which express the construct.Type: ApplicationFiled: June 9, 2009Publication date: April 28, 2011Inventors: Yuti Chernajovsky, Richard Neve, Marc Feldmann
-
Publication number: 20100310515Abstract: The present provides a fusion protein comprising a latency associated peptide (LAP) and a pharmaceutically active agent in which the LAP and the pharmaceutically active agent are connected by an amino acid sequence comprising an aggrecanase proteolytic cleavage site.Type: ApplicationFiled: December 17, 2008Publication date: December 9, 2010Applicant: QUEEN MARY & WESTFIELD COLLEGEInventors: Yuti Chernajovsky, Gillian Adams
-
Patent number: 7307147Abstract: The present invention provides a method for providing latency to a pharmaceutically active agent. The method has application in overcoming the toxic effect of systemic administration of potent biological agents. The method comprises associating a fusion protein comprising a latency associated peptide and a proteolytic cleavage site with a pharmaceutically active agent. The fusion protein also has application in providing site specific activation to a latent pharmaceutically active agent.Type: GrantFiled: September 20, 2006Date of Patent: December 11, 2007Assignee: Queen Mary and Westfield CollegeInventors: Yuti Chernajovsky, Hanna Stina Dreja, Gillian Adams
-
Publication number: 20070031925Abstract: The present invention relates to a receptor molecule which binds to TNF comprising all or a functional portion of the extracellular domain (ECD) of two or more TNF-Rs linked via one or more polypeptide linkers. The receptor can further comprise a signal peptide of a secreted protein, such as the signal peptide of the extracellular domain of the TNF-R or the signal peptide of a cytokine. The invention also relates to isolated DNA encoding a receptor molecule which binds to TNF, comprising two or more sequences encoding all or a functional portion of the ECD of TNF-Rs linked via one or more sequences encoding a polypeptide linker. The invention further relates to a method of making a construct which expresses all or a functional portion of the ECD of two or more TNF-Rs linked via one or more polypeptide linkers and cells which express the construct.Type: ApplicationFiled: May 26, 2006Publication date: February 8, 2007Inventors: Yuti Chernajovsky, Richard Neve, Marc Feldmann
-
Publication number: 20070015253Abstract: The present invention provides a method for providing latency to a pharmaceutically active agent. The method has application in overcoming the toxic effect of systemic administration of potent biological agents. The method comprises associating a fusion protein comprising a latency associated peptide and a proteolytic cleavage site with a pharmaceutically active agent. The fusion protein also has application in providing site specific activation to a latent pharmaceutically active agent.Type: ApplicationFiled: September 20, 2006Publication date: January 18, 2007Inventors: Yuti Chernajovsky, Hanna Dreja, Gillian Adams
-
Patent number: 7141392Abstract: The present invention provides a method for providing latency to a pharmaceutically active agent. The method has application in overcoming the toxic effect of systemic administration of potent biological agents. The method comprises associating a fusion protein comprising a latency associated peptide and a proteolytic cleavage site with a pharmaceutically active agent. The fusion protein also has application in providing site specific activation to a latent pharmaceutically active agent.Type: GrantFiled: January 7, 2004Date of Patent: November 28, 2006Assignee: Queen Mary and Westfield CollegeInventors: Yuti Chernajovsky, Hanna Stina Dreja, Gillian Adams
-
Patent number: 7070783Abstract: The present invention relates to a receptor molecule which binds to TNF comprising all or a functional portion of the extracellular domain (ECD) of two or more TNF-Rs linked via one or more polypeptide linkers. The receptor can further comprise a signal peptide of a secreted protein, such as the signal peptide of the extracellular domain of the TNF-R or the signal peptide of a cytokine. The invention also relates to isolated DNA encoding a receptor molecule which binds to TNF, comprising two or more sequences encoding all or a functional portion of the ECD of TNF-Rs linked via one or more sequences encoding a polypeptide linker. The invention further relates to a method of making a construct which expresses all or a functional portion of the ECD of two or more TNF-Rs linked via one or more polypeptide linkers and cells which express the construct.Type: GrantFiled: April 2, 1999Date of Patent: July 4, 2006Assignee: The Mathilda and Terence Kennedy Institute of RheumatologyInventors: Yuti Chernajovsky, Richard Neve, Marc Feldmann
-
Patent number: 7067495Abstract: Compositions and methods are described that decrease or inhibit osteonectin activity in tumor cells, including cancer cells. The cells cease to be tumor-like, or become less tumor-like. Pharmaceutical composition and therapies based thereon are also described.Type: GrantFiled: June 28, 1999Date of Patent: June 27, 2006Assignee: Fundacion Instituto LeloirInventors: Osvaldo Luis Podhajcer, Maria Fernanda Ledda, Soraya Karina Adris, Alicia Ines Bravo, Jose Mordoh, Yuti Chernajovsky
-
Patent number: 6942853Abstract: This invention provides a nucleic acid construct comprising a first nucleic acid sequence encoding a pharmaceutically active agent and a second nucleotide sequence encoding a latency associated peptide, in which a nucleic acid sequence encoding a proteolytic cleavage site is provided between the first and second nucleic acid sequences. The invention further provides a fusion protein comprising a latency associated peptide and a proteolytic cleavage site wherein the fusion protein is associated with a pharmaceutically active agent. Also disclosed are processes for preparing the construct and fusion protein, methods of treatment using the construct and fusion protein and pharmaceutical compositions containing the construct and fusion protein.Type: GrantFiled: January 9, 2001Date of Patent: September 13, 2005Assignee: Queen Mary and Westfield CollegeInventors: Yuti Chernajovsky, Hanna Stina Dreja, Gillian Adams
-
Publication number: 20040147444Abstract: The present invention provides a method for providing latency to a pharmaceutically active agent. The method has application in overcoming the toxic effect of systemic administration of potent biological agents. The method comprises associating a fusion protein comprising a latency associated peptide and a proteolytic cleavage site with a pharmaceutically active agent. The fusion protein also has application in providing site specific activation to a latent pharmaceutically active agent.Type: ApplicationFiled: January 7, 2004Publication date: July 29, 2004Inventors: Yuti Chernajovsky, Hanna Stina Dreja, Gillian Adams
-
Publication number: 20020151478Abstract: This invention provides a nucleic acid construct comprising a first nucleic acid sequence encoding a pharmaceutically active agent and a second nucleotide sequence encoding a latency associated peptide, in which a nucleic acid sequence encoding a proteolytic cleavage site is provided between the first and second nucleic acid sequences. The invention further provides a fusion protein comprising a latency associated peptide and a proteolytic cleavage site wherein the fusion protein is associated with a pharmaceutically active agent. Also disclosed are processes for preparing the construct and fusion protein, methods of treatment using the construct and fusion protein and pharmaceutical compositions containing the construct and fusion protein.Type: ApplicationFiled: January 9, 2001Publication date: October 17, 2002Inventors: Yuti Chernajovsky, Hanna Stina Dreja, Gillian Adams